Pharmacologic decoupling of IRBC activation from anabolic collapse redefines ribosome biogenesis inhibition as a selective tumor suppressive strategy
Sandra Menoyo, Berta Forcada, Zoi Mastora, Pau Bosch-i-Crespo, Francisco D. Morón-Duran, Cristina Santos, Ramón Salazar, Antonio Gentilella
This study shows that inhibiting ribosome biogenesis can selectively activate the IRBC checkpoint in TP53-proficient cells, offering a new therapeutic strategy for cancer.
bioRxiv · Aug 27, 2026 · PreprintCancer Biology